Nov 15, 2016
Copenhagen, Denmark – 15 November 2016. Monsenso announced today that the Norwegian hospital, Lovisenberg Diakonale Sykehus, will begin a pilot study with the Monsenso mHealth solution that aims to reduce hospital readmissions of individuals with bipolar disorder. Lovisenberg was signed up as a customer by Computas, Monsenso’s partner in Norway.
The pilot study, which will include individuals with bipolar disorder, aims to reduce hospital readmissions by using the Monsenso mHealth solution to intervene at an early stage.
Thomas Lethenborg, CEO at Monsenso, said that Lovisenberg would conduct a ten-month pilot study to determine if the solution should be widely implemented with other mental illnesses.
“Lovisenberg is committed to finding innovative solutions that help them provide better care to their patients in a more cost-efficient way. With the implementation of the Monsenso mHealth solution, a patient’s historical, aggregated data will be available more easily,” Mr Lethenborg added.
Kim Petersen, Executive Director at Computas AS, said “We are thrilled to have signed up our first customer with Monsenso. This type of technology gives new opportunities for the integration of mobile health into the existing mental health services in Norway; and I am confident that once clinicians start experiencing the clinical and financial benefits of implementing the solution, we will sign up more customers in no time!”
Andreas Joner, Head of Clinic at Lovisenberg, said the trial would allow them to investigate how a remote patient monitoring solution can be used to improve patient care and patient engagement.
“The Monsenso mHealth solution will help us to access and analyse data in a more efficient way. Besides, since most people carry their smartphones all the time, patients can answer their self-assessments and clinical questionnaires wherever they are, without feeling self-conscious,” said Andreas Joner.
The Monsenso mHealth solution for mental illnesses is based on a triple-loop treatment model that connects patients, carers and clinicians and has the potential to reduce hospital readmissions of bipolar patients.
Patients use a smartphone to fill in routine self-assessments that reveal their current state of mind and collect sensor data. The smartphone app also works as a self-help tool that allows patients to manage their symptoms and the behaviours that trigger those symptoms. Carers are also given a smartphone that allows them to assess the overall well-being of the one they care for, and make notes that are shared with the patient and the clinician.
Clinicians use a web portal that provides historical information on each patient, including routine self-assessments and clinical questionnaires. The portal also allows them to obtain an overview of their patients’ illness progression, symptoms, medication compliance, and medical record keeping.
With more than 1300 employees, Lovisenberg Diakonale Sykehus delivers effective treatment and outpatient care across its multiple sites. The hospital provides specialist care in mental health.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
Tone Hærem
Communications Director
Lovisenberg Diakonale Sykehus
tone.harem@lds.no
Pål Vermund Knudsen
Sales Director
Computas AS
pal.vermund.knudsen@computas.com
About Lovisenberg Diakonale Sykehus
Lovisenberg Diaconal Hospital provides specialised health care services in mental health and internal medicine for 180,000 inhabitants of four City Districts in Oslo (inner city). In addition, mental health services are offered to several other city boroughs. The surgical department performs scheduled operations, and has one of the leading orthopaedic units in Norway. The hospital has 234 beds, more than 2,000 employees, and an extensive out-patient facility. It is a non-profit, privately owned organisation, all services provided are within Public Health. Our mission is to offer diagnostics, treatment, and follow up services of a high quality to all our patients, with equality and respect. Being innovative and finding new solutions is part of this.
About Computas
Computas is an international IT solutions provider based in Norway, delivering solutions all over the world. We deliver services and solutions for work processes and collaboration. Our core competence is systems development, architecture and integration, project management and consulting. We have unique experience, deliver high quality in all projects, and work closely with customers to make the best solutions. The health care system in Norway is changing, and there is a need for smart solutions that can ensure quality and improve the efficiency of health services. The key to solving these challenges is through better use of IT. We are prepared to contribute with our expertise and our solutions aimed at patients and health care workers. We have delivered everything from work process solutions to apps to help the health sector to work more efficiently and to help patients to have better safety.[/vc_column_text][vc_column_text]You can download this article as PDF in English, Danish and Norwegian
Aug 30, 2016
Copenhagen, Denmark – 30 August 2016. Monsenso, the Copenhagen-based technology company developing mHealth solutions for mental illnesses, today announced a partnership with The Black Dog Institute in Australia.
Black Dog Institute is a pioneer in the identification, prevention and treatment of mental illness and the promotion of well-being. The Institute will conduct feasibility studies to determine if the Monsenso mHealth solution can be used to collect much needed data for a number of large-scale mental health trials.
“The mission of Monsenso and that of Black Dog are highly aligned. We both aim to enable better mental health care through innovation and science, therefore this is an exciting moment for both parties” said Thomas Lethenborg, CEO at Monsenso. “Monsenso is looking to build sustainable, long-term partnerships, with the ultimate goal of delivering better care, to more people, and at lower cost.”
As part of the on-going collaboration between Monsenso and the Black Dog Institute, Mads Frost, Chief Product Officer of Monsenso, has been invited to participate as a guest-speaker at the conference “Humans and Machines: A Quest for Better Mental Health” organised by Black Dog.
Helen Christensen, Director of the Black Dog Institute, said the trial would allow them to collect real-time information using a device that most people carry at all times – their Smartphone. “Our focus will be on collecting self-reported daily mood ratings and activity data that may be used to predict changes in mental health conditions over time. Ultimately these sorts of tools can be used to deliver real time assistance to those in distress at the time they most need help. However, like all good research and development projects, our aim is to test the validity of these approaches; their feasibility and the extent that they can provide better health care services. Ultimately, we hope to use these sorts of tools in our national programmes involving youth mental health and suicide prevention.”
The Monsenso mHealth solution for mental illnesses holds a CE mark and a TGA certification and it has been technically and clinically validated in clinical evaluation studies and randomised clinical trials. Furthermore, Monsenso is in the process of obtaining the ISO 13485 and ISO 27001.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
Gayle McNaught
Head of Public Affairs
The Black Dog Institute
g.mcnaught@blackdog.org.au
About The Black Dog Institute
The Black Dog Institute is a not-for-profit organisation which is internationally recognised as a pioneer in the identification, prevention and treatment of mental illnesses, and the promotion of well-being. We are dedicated to improving the lives of people affected by mental illness through the rapid translation of high quality research into improved clinical treatments, increased accessibility to mental health services and delivery of long-term public health solutions. Our unique approach incorporates clinical services with our cutting-edge research, our health professional training and community education programs. We combine expertise in clinical management with innovative research to develop new, and more effective, strategies for people living with mental disorders. For more information visit www.blackdoginstitute.org.au
You can download this article as PDF in English and Danish
Aug 15, 2016
Copenhagen, Denmark – 16 August 2016. Monsenso, today announced that its mHealth solution received a Class I medical-device certification, from the Australian Register of Therapeutic Goods Administration (TGA).
The mHealth solution received the TGA certification in cooperation with Emergo, a consultancy company specialising in regulatory compliance for medical devices, with funding from the Danish Market Development Fund.
Thomas Lethenborg, CEO at Monsenso, commented “We are very satisfied that the Monsenso mHealth solution received the TGA certification and is now ready to be launched in the Australian market. Although we already have a customer in Australia, this certification provides us with the means to commercialise the solution nation-wide.”
This certification guarantees that a manufacturer’s product meets the essential requirements stipulated by the Australian Register of Terapeutic Administration.
“Holding the right certifications, and offering a high level of data security is essential for healthcare providers in all markets –including Australia. Therefore, it is important that Monsenso possesses the necessary quality control standards and adequate security measures to succeed world-wide” added Mr. Lethenborg.
The next steps for Monsenso are to obtain the ISO 13485 Certification; the ISO 27001 Data Security Certification; and to become HIPAA and FDA compliant. These certifications will be also obtained with the monetary support granted by the Danish Market Development Fund. You can download this article as PDF in English and Danish.
Note:
As of 23 May 2023, Monsenso does no longer hold the TGA certification.
Jun 21, 2016
Copenhagen, Denmark – 21 June 2016. Monsenso, a Copenhagen-based technology company, announced today that the NHS Foundation Trust of Central Northwest London (CNWL) will implement the Monsenso mobile health (mHealth) solution to support the treatment of young patients suffering from schizophrenia.
The pilot, which will run from July to December, will be implemented amongst young patients aged 18 to 24, across Kensington, Chelsea, Westminster, Milton Keynes, and Hillingdon. It will be the first step prior to rolling out the solution more widely and fully integrating it with TTP SystmOne enabling clinicians to access all patient data from one place.
The objective of the pilot is to evaluate the clinical and economic benefits of using the Monsenso solution such as reducing the number of psychiatric readmissions and using the latest technology to collect and analyse patient data.
With the help of the Monsenso mHealth solution, clinicians will be able to identify the triggers and early warning signs of the young patients and intervene at an early stage to avoid emergency situations. The clinical web portal provides clinicians with an insight into the correlation between a patient’s behavioural patterns and the illness enabling them to provide a more informed and better treatment to a larger number of patients.
Thomas Lethenborg, CEO at Monsenso ApS, said “CNWL aims to offer its patients high-quality treatment with the latest technology available. With the implementation of the Monsenso mHealth solution, clinicians will be able to access a patient’s historical aggregated data, which will help them offer a better treatment based on evidence.”
Dr Pramod Prabhakaran, Divisional Medical Director of CNWL, said “We are working closely with our service users, partners, and stakeholders to be more responsive towards people’s needs. The implementation of the Monsenso mHealth solution is part of a wider service redesign to improve our community mental health services across North West London.”
For additional information about Monsenso contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
For additional information about CNWL contact:
Mike Waddington
Communications Director
CNWL
+44 77 40 42 28 73
mikewaddington@nhs.net
About CNWL
Central and North West London NHS Foundation Trust is one of the largest trusts in the UK, caring for people with a wide range of physical and mental health needs. We provide a wide range of services to treat people with a variety of health needs. In broad terms, these include common physical health problems, long-term conditions, mental health, learning disabilities, eating disorders, addictions and sexual health. We are here to provide support for people through every stage of life. The majority of our services are provided in the community, which means treating people in their homes or from clinics close to home. Where community care is not possible we offer a number of facilities to treat people in the hospital or residential environments. We also provide healthcare in prisons in London and the surrounding areas. We are committed to providing services that meet the needs of the people who use them, and we actively encourage involvement from local people who can help make a difference.[/vc_column_text][vc_column_text]You can download this article as PDF in English and Danish
Apr 14, 2016
Copenhagen, Denmark – 14 April 2016. Monsenso ApS announced today that Thomas Lethenborg, CEO of Monsenso participated as a guest speaker at WHO mental health meeting. The two-day event titled “Out of the Shadows: Making Mental Health a Global Development Priority” was co-hosted by the World Bank Group and World Health Organization (WHO).
The WHO mental health meeting, which took place in Washington D.C. on April 13-14, aimed to include mental health as a priority in the global development agenda. Additionally, Thomas Lethenborg will participate in a panel discussion titled “Leveraging New Technologies for Improving Access to Care and Designing New Interventions.”
Mental health has received inadequate attention by policy makers and society in general. However, mental and behavioural disorders impose an enormous illness burden in addition to being very costly to country economies. According to WHO, in 2010 the global cost of mental disorders was estimated to be approximately US$2.5 trillion and by 2030 that figure is projected to go up by 140%, to US$6.0 trillion.
It has been estimated that the vast majority of low and middle-income countries allocate less than 1% of their health budgets to mental health, making them ill-equipped to deal with this “invisible” and often-ignored challenge.
With regards to his participation at the event, Thomas Lethenborg, said: “Due to these existing challenges, mental health must become a priority in the global health agenda and mHealth technology has the potential to bring better treatment to more people at lower cost.”
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com[/vc_column_text][vc_column_text]You can download this article as PDF in English and Danish
Mar 15, 2016
Copenhagen, Denmark – 15 March 2016. Monsenso ApS, an innovation leader in mobile health (mHealth) solutions for mental health, announced today the development of a triple-loop mHealth solution that enables information-sharing between patients, carers and clinicians to support the treatment of 1,000 individuals suffering from schizophrenia.
The mHealth solution, designed and developed by Monsenso, will provide healthcare professionals and family caregivers with access to the patient’s information.
Patients will be encouraged by their care providers to download the Monsenso smartphone app that will allow them to invite their care providers and family caregivers to access their data.
The smartphone app will be used to fill in routine self-assessments that reveal their current state of mind, and to collect sensor data. It can also be used as a self-management tool that allows patients to manage their symptoms and the behaviours that trigger those symptoms.
Once invited by the patient, a family caregiver will be able to use a similar app to access the patient’s aggregated data and fill in the routine assessments evaluating the patient’s state of mind.
Healthcare professionals will use a web portal where they can access all the data collected by the patients’ and caregivers’ smartphones anytime, anywhere. The web portal enables clinicians to view relevant information related to each patient.
In relation to the development of the triple-loop solution, Thomas Lethenborg, CEO at Monsenso, commented. “We are approaching treatment in a way that has never been done before. There are currently a few mHealth solutions that offer a double-loop treatment model for patients and care providers. However, Monsenso will be the first company ever to develop and implement an mHealth platform that involves patients, care providers and family caregivers in the treatment of a mental illness. The caregiver module, which is currently under development, will be ready to be rolled out in Q3 2016, and will initially be used for two years.”
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
You can download this article as PDF in English and Danish
